Critical Therapeutics Inc: Premium Company Profile

Publication Date	December 2007
Publisher	Datamonitor
Product Type	Databook
Pages	50
ISBN Number	not applicable
Product Code	DAT09434

Price

£265.00
approximately: $495 | €336

PRINT £265 ($495 | €336)

Order above formats by FAX

Summary

Introduction

Critical Therapeutics is a biopharmaceutical company focused on the development and commercialization of products for respiratory, inflammatory and critical care diseases. It has marketed products such as ZYFLO and ZYFLO CR and is developing Anti-HMGB-1 Mab for rheumatoid arthritis and also formulations of zileuton.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Critical Therapeutics develops products to treat respiratory, inflammatory and critical care diseases. The company' strategic collaborations and licensing agreement are the primary reasons for the rapid development of products and growing revenues.

The company's total revenues increased from $1 million in 2003 to $13 million in 2006. Critical Therapeutics' product sales which is entirely from ZYFLO, reported $0.4 million in 2005 and increased by 94% to $7 million in 2006. The company's collaboration revenues recorded $6 million in 2006 compared to $1 million in 2003.

Critical Therapeutics' total revenues are forecasted to expand by a CAGR of 53% over the period 2006-2010. The company anticipates product revenues to rise from $7 million in 2006 to $60 million in 2010 at a CAGR of 71%. Revenues from the collaboration agreements are expected to grow with an absolute growth of $7 million during 2006-2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Products & Services
- Marketed Products
- Pipeline Products
- Historical Product Sales
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Product Development
- Sales
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: Critical Therapeutics - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Critical Therapeutics - Key Strategic Revenues, 2002-2006 ($ Mn)
- Figure 3: Critical Therapeutics - Key Strategic Revenues, 2006-2010 ($ Mn)
- Table 1: Critical Therapeutics - Key Facts
- Table 2: Critical Therapeutics - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 3: Critical Therapeutics - Key Events Impacting Share Price Performance
- Table 4: Critical Therapeutics - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 5: Critical Therapeutics - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 6: Critical Therapeutics - Balance Sheet, 2002-2006 ($ Mn)
- Table 7: Critical Therapeutics - Cash Flow, 2002-2006 ($ Mn)
- Table 8: Critical Therapeutics - Revenue Breakdown by Division, 2002-2006 ($ Mn)
- Table 9: Critical Therapeutics - Marketed Products
- Table 10: Critical Therapeutics - in-house Pipeline Products
- Table 11: Critical Therapeutics - Collaboration Products
- Table 12: Critical Therapeutics - Historical Product Sales, 2002-2006 ($ Mn)
- Table 13: Critical Therapeutics - Forecast Sales, 2006-2010 ($ Mn)
- Table 14: Critical Therapeutics - Key Competitors
- Table 15: Critical Therapeutics- Key Suppliers
- Table 16: Critical Therapeutics - Key Clients
- Table 17: Critical Therapeutics - Key Shareholders
- Table 18: Critical Therapeutics - SWOT Analysis Summary
- Table 19: Critical Therapeutics - Value Chain Analysis
- Table 20: Critical Therapeutics - Scorecard
- Table 21: Critical Therapeutics - Key Employees
- Table 22: Critical Therapeutics - Financial and Operational Overview